RIPK2-IN-8

CAT: 0804-HY-175026Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-175026Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
RIPK2-IN-8 is an orally active and highly selective RIPK2 inhibitor (IC50 = 11 nM) . RIPK2-IN-8 is highly selective for RIPK2 over RIPK1 (IC50 > 30,000 nM) and has a moderate inhibitory effect on RIPK3 (IC50 = 44.61 nM) . RIPK2-IN-8 inhibits the NOD2-RIPK2 signaling pathway and the expression of the inflammatory cytokines IL-6 and TNFα, thereby exerting anti-inflammatory effects. RIPK2-IN-8 has demonstrated anti-inflammatory and hepatoprotective effects in an acute liver injury (ALI) model and can be used in ALI research[1].
CAS Number
[3036254-29-9]
UNSPSC
12352005
Target
Interleukin Related; NF-κB; p38 MAPK; RIP kinase
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CCC(NC1CCC(C2=CC(N=CN=C3NC4=CC(N=CS5)=C5C=C4F)=C3S2)=CC1)=O
Molecular Formula
C22H20FN5OS2
Molecular Weight
453.56
References & Citations
[1]Zhao H, et al. Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy. Eur J Med Chem. 2025 Jul 5;297:117932.|[2]Zhao H, et al. Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy. Eur J Med Chem. 2025 Jul 5;297:117932.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6; RIPK2; RIPK3